BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 28944998)

  • 1. Enhanced immune response induced by P5 HER2/neu-derived peptide-pulsed dendritic cells as a preventive cancer vaccine.
    Gholizadeh Z; Tavakkol-Afshari J; Nikpoor AR; Jalali SA; Jaafari MR
    J Cell Mol Med; 2018 Jan; 22(1):558-567. PubMed ID: 28944998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer.
    Zamani P; Navashenaq JG; Nikpoor AR; Hatamipour M; Oskuee RK; Badiee A; Jaafari MR
    J Control Release; 2019 Jun; 303():223-236. PubMed ID: 30999007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN.
    Mansourian M; Badiee A; Jalali SA; Shariat S; Yazdani M; Amin M; Jaafari MR
    Immunol Lett; 2014 Nov; 162(1 Pt A):87-93. PubMed ID: 25086399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer.
    Zamani P; Teymouri M; Nikpoor AR; Navashenaq JG; Gholizadeh Z; Darban SA; Jaafari MR
    Eur J Cancer; 2020 Apr; 129():80-96. PubMed ID: 32145473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model.
    Alipour Talesh G; Ebrahimi Z; Badiee A; Mansourian M; Attar H; Arabi L; Jalali SA; Jaafari MR
    Immunol Lett; 2016 Aug; 176():57-64. PubMed ID: 27260485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous activation of T helper function can augment the potency of dendritic cell-based cancer immunotherapy.
    Teramoto K; Ohshio Y; Fujita T; Hanaoka J; Kontani K
    J Cancer Res Clin Oncol; 2013 May; 139(5):861-70. PubMed ID: 23411688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Immunogenicity Against a Her2/neu-Derived Peptide by Employment of a Pan HLA DR-Binding Epitope and CpG in a BALB/c Mice Model.
    Tahaghoghi-Hajghorbani S; Tavakkol-Afshari J; Jaafari MR; Ghaffari-Nazari H; Masoumi E; Jalali SA
    Anticancer Agents Med Chem; 2017; 17(6):851-858. PubMed ID: 27924731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination epidermal growth factor receptor variant III peptide-pulsed dendritic cell vaccine with miR-326 results in enhanced killing on EGFRvIII-positive cells.
    Li J; Wang F; Wang G; Sun Y; Cai J; Liu X; Zhang J; Lu X; Li Y; Chen M; Chen L; Jiang C
    Oncotarget; 2017 Apr; 8(16):26256-26268. PubMed ID: 28412740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
    Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
    Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
    Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
    Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
    Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
    Kodumudi KN; Ramamoorthi G; Snyder C; Basu A; Jia Y; Awshah S; Beyer AP; Wiener D; Lam L; Zhang H; Greene MI; Costa RLB; Czerniecki BJ
    Front Immunol; 2019; 10():1939. PubMed ID: 31475002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer.
    Shariat S; Badiee A; Jalali SA; Mansourian M; Yazdani M; Mortazavi SA; Jaafari MR
    Cancer Lett; 2014 Dec; 355(1):54-60. PubMed ID: 25224570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving Multi-Epitope Long Peptide Vaccine Potency by Using a Strategy that Enhances CD4+ T Help in BALB/c Mice.
    Ghaffari-Nazari H; Tavakkol-Afshari J; Jaafari MR; Tahaghoghi-Hajghorbani S; Masoumi E; Jalali SA
    PLoS One; 2015; 10(11):e0142563. PubMed ID: 26556756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoliposomes carrying HER2/neu-derived peptide AE36 with CpG-ODN exhibit therapeutic and prophylactic activities in a mice TUBO model of breast cancer.
    Barati N; Nikpoor AR; Razazan A; Mosaffa F; Badiee A; Arab A; Gholizadeh Z; Behravan J; Jaafari MR
    Immunol Lett; 2017 Oct; 190():108-117. PubMed ID: 28736158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful tumor eradication was achieved by collaboration of augmented cytotoxic activity and anti-angiogenic effects following therapeutic vaccines containing helper-activating analog-loaded dendritic cells and tumor antigen DNA.
    Teramoto K; Kontani K; Fujita T; Ozaki Y; Sawai S; Tezuka N; Fujino S; Itoh Y; Taguchi O; Kannagi R; Ogasawara K
    Cancer Immunol Immunother; 2007 Mar; 56(3):331-42. PubMed ID: 16896967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Investigation of the combination of anti-PD-L1 mAb with HER2/neu-loaded dendritic cells and QS-21 saponin adjuvant: effect against HER2 positive breast cancer in mice.
    Özverel CS; Uyanikgil Y; Karaboz İ; Nalbantsoy A
    Immunopharmacol Immunotoxicol; 2020 Aug; 42(4):346-357. PubMed ID: 32515626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA vaccines targeting the encoded antigens to dendritic cells induce potent antitumor immunity in mice.
    Cao J; Jin Y; Li W; Zhang B; He Y; Liu H; Xia N; Wei H; Yan J
    BMC Immunol; 2013 Aug; 14():39. PubMed ID: 23941509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
    Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
    Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.